Home

Executives

Acquisitions/Mergers

Funding

FDA Updates

Clinical Trials

Medical Device News

Insights on the High Content Screening Global Market to 2027

Latest Posts

Abraham Verghese MD Appointed to the Board of Directors of Athos Therapeutics

"Abraham Verghese MD is a highly distinguished physician, humanist, administrator, and adviser," said Allan Pantuck, MD, MS, FACS, Chairman & CMO.

University of Nebraska Medical Center and ANANDA Scientific announce FDA approval of the IND for a Clinical Trial exploring Treatment for Post-Traumatic Stress Disorder

The study will evaluate the effectiveness of Nantheia™ ATL5, an investigational drug-using cannabidiol in ANANDA’s proprietary delivery technology. An investigational new drug (IND) application for the trial has been approved by the FDA.

BRIM Biotechnology & Ora Announce New Partnership

BRIM Biotechnolgy notes the new partnership builds on the success of our previous collaboration for Phase 2 trials and will help to speed the progression of BRM421 through late-stage clinical development toward regulatory filing.

Cytel Designed & Led TOGETHER Trial Wins Society of Clinical Trial’s David Sackett Trial of the Year Award

TOGETHER trial has enrolled over 6000 patients in 22 research sites in Brazil.  It is now expanding to Pakistan and South Africa, Rwanda, DRC, and Vietnam.

High Content Screening Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027″ report has been added to ResearchAndMarkets.com’s offering.

The global high content screening market reached a value of US$ 1.1 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 1.8 Billion by 2027, exhibiting at a CAGR of 8.7% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

High content screening (HCS), or high content analysis, refers to an analytical method of automated microscopy that uses visualization tools to obtain quantitative data from cell populations. It is an integration of modern cell biology, flow cytometry and robotic handling that involves fluorescence imaging for analyzing various biochemical and physical characteristics of the sample cells. This aids in drug discovery, complex multivariate drug profiling and toxicity studies, while utilizing robots, detectors and software to monitor the entire process.

The increasing prevalence of neurodegenerative diseases across the globe, such as Alzheimer’s and Parkinson’s, is one of the key factors driving the market growth. The rising need for cost-effective drug discovery systems in the pharmaceutical industry is also providing a boost to the market growth. In comparison to the traditionally used methods, HCS solutions prove to be inexpensive and resource- and time-efficient for analyzing the potential toxicity of chemicals and complex substances.

Advancements in informatics solutions and imaging instruments are acting as another growth-inducing factor. HCS equipment manufacturers are producing innovative equipment that is integrated with software platforms and artificial intelligence (AI) systems to enhance the visualization capabilities of the devices. In line with this, the development of automated systems for analyzing cell separation and scalability has further enhanced the adoption of HCS technology. Other factors, including the rising geriatric population and increasing investments in the research and development (R&D) of advanced screening systems, are projected to drive the market further.

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Biotek Instruments Inc., Danaher Corporation, GE Healthcare, Merck Millipore, Perkinelmer Inc., Tecan Group Ltd., Thermo Fisher Scientific, Yokogawa Electric Corporation, etc.

Key Questions Answered in This Report:

  • How has the global high content screening market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What has been the impact of COVID-19 on the global high content screening market?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global high content screening market and who are the key players?
  • What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global High Content Screening Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product
6.1 Instruments
6.1.1 Market Trends
6.1.2 Major Types
6.1.2.1 Cell Imaging and Analysis Systems
6.1.2.2 Flow Cytometers
6.1.3 Market Forecast
6.2 Consumables
6.2.1 Market Trends
6.2.2 Major Types
6.2.2.1 Reagents & Assay Kits
6.2.2.2 Microplates
6.2.2.3 Others
6.2.3 Market Forecast
6.3 Software
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Services
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Accessories
6.5.1 Market Trends
6.5.2 Market Forecast

7 Market Breakup by Application
7.1 Target Identification and Validation
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Primary Screening and Secondary Screening
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Toxicity Studies
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Compound Profiling
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast

8 Market Breakup by End-User
8.1 Pharmaceutical and Biotechnology Companies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Academic and Government Institutes
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Contract Research Organizations (CROs)
8.3.1 Market Trends
8.3.2 Market Forecast

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Indicators

14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Becton, Dickinson and Company
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Bio-Rad Laboratories Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Biotek Instruments Inc.
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 Danaher Corporation
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 GE Healthcare
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.6 Merck Millipore
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.7 Perkinelmer Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Tecan Group Ltd.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.9 Thermo Fisher Scientific
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Yokogawa Electric Corporation
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis

For more information about this report visit here.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine